Revenue
2024
2025
Xilio Therapeutics, Inc. (XLO)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | — | — | — | — |
| Research & development | $56.0M | $41.2M | $52.1M | $59.2M | $51.2M | $43.9M |
| Operating expenses | $85.7M | $66.9M | $79.1M | $89.1M | $75.0M | $54.6M |
| Operating income | −$42.0M | −$60.6M | −$79.1M | −$89.1M | −$75.0M | −$54.6M |
| EBITDAderived | −$40.4M | −$58.9M | −$77.2M | −$87.3M | −$73.5M | −$53.5M |
| Net income | −$35.0M | −$58.2M | −$76.4M | −$88.2M | −$75.8M | −$55.2M |
| Basic EPSper diluted share | -$4.19 | -$15.24 | -$2.78 | -$3.22 | -$13.52 | -$105.42 |
| Diluted EPSper diluted share | -$4.19 | -$15.24 | -$2.78 | -$3.22 | -$13.52 | -$105.42 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 26, 2026Form 4 | Shannon James SamuelDirector | BuyCommon Stock | 5.0K | $8.79 | $43.9K | 10.0K |
| Feb 13, 2026Form 4 | GILEAD SCIENCES, INC.TenPercentOwner | BuyPrefunded Warrants (right to buy) · derivative | 3.74M | $0.53 | $1.98M | 40.38M |
| Jan 2, 2026Form 4 · 10b5-1 | Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | SellCommon Stock | 1.8K | $0.64 | $1.2K | 6.4K |
| Jan 2, 2026Form 4 · 10b5-1 | Frankenfield Christopher JamesChief Financial Officer | SellCommon Stock | 7.0K | $0.64 | $4.5K | 24.8K |
| Jun 17, 2025Form 4 | Shannon James SamuelDirector | BuyCommon Stock | 25.0K | $0.69 | $17.3K | 70.0K |